Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
definitely not "repeating" Geralds Tweet in my response here
I am taking issue with it (in case you have not perceived that, and needed it to be clarified or pointed out to you), as follows:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173206313
uh oh - this is even more alarming and can't be good for TOMDF shareholders:
printing $0.0003 Joey
all anybody needs to know
you have the illustrious CEO to thank
and no one else
smH / sad but true…!
MOO
good man Sir
I’m in rank and file…!
BAF MONI
not lying - there's only you who is stating I am...
which make you the liar...!
cop a clue, Tollovid will have little play in Covid or LH Covid
keep listening to Sanjay and dreaming of TOMDF hitting $300 per share
maybe the highly touted Kingcarlx Todos Medical "Ambassador" will convince you Tollovid is shite
even Gerald is telling you he just doesn't know...read and comprehendo amigo
it will be a decade or two before they get a handle on curing or even arresting this ever mutating SARS virus
SMH - nuff said
MOO sophomoric
what - so now because of this "stoopid" article...
you think Gerald has the LH Covid or Covid cure down pat and is cornering the market with Tollovid...?
here let me help you with that, as a refresher - you know - just in case you forgot and have memory lapse....
and after all this time, money and expense promoting Tollovid as the next big COVID thing...
this is what the illustrious highly over-paid and twice failed Stanford Univ. undergrad "Financial Engineering" flunky has to say:
if you've invested in TOMDF all this time during the pre & post Pandemic, waiting on significant results from Tollovid...
then this above response from Gerald is simply frightening, lame, mindless and completely unhinged....!
oh here's another news flash from Gerald - inventor of the Anti-Covid pill - my royal right cheek arse...!
lying sack o shite - are ye...?
FYI not all people know how to navigate the medical professional hierarchy, and that surprisingly may include a nurse or two
SMH - you simply can't make this stuff up
printing $0003 and heading lower - is all anyone really needs to know folks
continue buying this shite is like throwing your money overboard...!
but keep listening to these TOMDF shills, touts and dolts - Gerald loves your money...!
MOO stoopid
well wel well, this can't be good for TOMDF shareholders
been in and out on swing trades since MONI was WOGI and then DYNS before that
remember them - maybe not as you weren’t around then
that 02/13/14 post was definitely was pre-MONI - so it has no relevance here
but here, let me help you with your posting content:
a stock is only as good as the time frame that it trades in
unless you're invested in stocks which have gone down the toilet via dilution, massive debt & toxic death spiral convertibles
MONI doesn’t have any of those here…
being new to a stock and potentially holding no position leaves one basically uninformed on its performance & history
that would make one wonder - what's one’s posting presence about, like trolling posts from a decade ago?
it’s kind of like the old saying: ”honey, look what the cat dragged home”
but hey, good fortunes to you in whatever security it is that you do hold
BAF MONI....!
for those whose memories are either honestly failing them
or who are dishonestly fabricating & obfuscating the truth ....
which by the way, happens a lot around the worthless TOMDF 9 Horsee Ranch & Stable grounds....
here's what was stated WRT COVID medical professionals - or following shills, touts and dolt's highly suspect "medical" advice:
right here - have gone nowhere
but then again - you already knew that eh Red...?
and that's right - John Petrosino - US ARMY ROTC - proud American patriot - selfless public servant - and proud of it
yeah - talk about old equipment I hear you using the latest model keyboard right here:
living in ones mothers basement, living off an allowance and spinning ratchets ain't too kewel either
TOMDF is a scam and a diluted toxic convertible non-reporting pinkie stinkie, trading at an pathetic and paltry $0.0004
glad I am above board, out in the open, and calling this POS for what it was all along...
but hey, here's to you and the Back Office Promo Boy failed TOMDF, AMBS and VERB pool party celebration
SMH - nuff said
MOO delinquent
here's all the lies about Todos, CEO and investors one really needs to know
have many if any ever come true...?
best check that TA Chart and OS share count while your on your playtime keyboard...!
TOMDF sham in PR Chronological Order and Timeline
Todos Medical Provides Corporate Update: Retooling to Focus on Long COVID Epidemic
Sep 26, 2023 11:01am EDT
Todos Announces Notice of Allowance From USPTO for Patent Application Covering Use of Compositions In Tollovid™ and Tollovir™ Ingredients
Aug 30, 2023 8:19am EDT
Todos Medical Enters Into Letter of Intent for Provista Diagnostics to License PCR-based Sepsis Diagnostic Test AcuSept LDT Rights From Acumen Diagnostics
Mar. 28, 2023
Todos Medical Begins Trading on the OTC Pink Marketplace
Mar. 27, 2023
Todos Medical Supports Long COVID Awareness Day
Mar. 15, 2023
Todos Medical Enters Into Moratorium on Conversions Agreement With Convertible Note Holders
Mar. 13, 2023
Todos Medical Initiates Validation Plan for PCR-based Avian Influenza A (H5N1, Bird Flu) Test at CLIA/CAP Testing Lab Provista Diagnostics
Feb. 14, 2023
Todos Medical to Present at the RHK 2022 Disruptive Growth Conference
Dec. 06, 2022
Todos Medical’s 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022
Nov. 29, 2022
Todos Medical to Attend World Antiviral Congress
Nov. 22, 2022
Todos Medical Enters Into Exclusive Worldwide Automated Retail Supply Agreement With Smart Automated Retail Network
Nov. 16, 2022
Todos Medical Terminates Tollovid™ Products License & Distribution Agreement with T-Cell Protect Hellas S.A.
Nov. 10, 2022
Todos Medical CLIA/CAP Lab Provista Submits Emergency Use Authorization Application for MonkeyPox PCR Test to US FDA
Oct. 14, 2022
Todos Medical Announces Successful Pilot Launch of Suite of PCR Testing Services by CLIA/CAP Lab Provista Diagnostics
Oct. 06, 2022
Todos Medical Receives Two Notices of Allowance from USPTO for AI-Based TBIA Pan-Cancer Blood Diagnostics Platform
Sep. 30, 2022
Todos Medical Announces USPTO Trademark Notice of Allowance for 3CL Protease Biomarker Diagnostics TolloTest™
Sep. 27, 2022
Todos Medical Enters Into $50M Contract to Supply Tollovid™ and CBD Products to Retail Distributor Company Nerd Hemp
Sep. 22, 2022
Todos Medical Announces NFL Hall of Famer Michael Irvin as Tollovid™ Sports Ambassador for #TolloUp Campaign
Sep. 16, 2022
Todos Medical Announces Preprint of Long COVID Case Study Participant with Confirmed Microclot and Hyperactivated Platelets who Benefitted from Tollovid
Sep. 15, 2022
Todos Medical & The Alchemist’s Kitchen to Host “Long COVID: An Integrated Approach” Event Benefitting Survivor Corps
Sep. 13, 2022
Todos Medical’s 3CL Protease Inhibitor Supplement Tollovid™ Featured in Wellness Magazine
Sep. 13, 2022
Todos Medical Partner NLC Pharma Assigns IP for Tollovir™, Tollovid™, and TolloTest™ into JV 3CL Pharma
Sep. 12, 2022
Todos Medical CEO Discusses Long COVID Economic Impact with Moneta Advisory Managing Partner Marc LoPresti
Sep. 09, 2022
Todos Medical Announce Kingcarlx as Brand Ambassador for the Tollovid #TolloUp Lifestyle Campaign
Sep. 02, 2022
Todos Medical Establishes Botanical Supplement Manufacturing Capabilities to Support Tollovid Global Expansion and Initiates CBD-A Production
Aug. 31, 2022
Todos Medical Expands COVID Onsite School Sample Collection to Include MonkeyPox Testing
Aug. 29, 2022
Todos Medical Announces Saliva-Only MonkeyPox Testing at CLIA/CAP Clinical Lab Provista Diagnostics
Aug. 26, 2022
Todos Medical Enrolls Female Long COVID Patient Unable to Secure Testing While Symptomatic for MonkeyPox into Provista Diagnostics Case Study Series
Aug. 25, 2022
Todos Medical Initiates MonkeyPox Diagnostic Case Studies After Being Approached by 4 Patients, Including 3 Women
Aug. 23, 2022
Todos Medical Announces Commercialization of Lesion and Saliva-Based MonkeyPox PCR Testing
Aug. 22, 2022
Todos Medical Announces Preprint of Data from First 100 Participants in IRB-waived Market Research Study of Supplementation with Tollovid in Long COVID
Aug. 19, 2022
Todos Medical Reports Pre-Print of Publication Detailing Tollovid Supplementation Following COVID-19 mRNA Vaccination in Long COVID
Aug. 15, 2022
Todos Medical Completes Trial Design for Tollovid™ Long COVID Clinical Study in Adults
Aug. 11, 2022
Todos Medical Announces PCR Validation of Wound and Respiratory Pathogen Panels at CLIA/CAP Lab Provista Diagnostics
Aug. 10, 2022
Todos Medical Announces First Two Contracts for PCR-based MonkeyPox Testing at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics
Aug. 08, 2022
Todos Medical Announces First Long COVID Clinic Laboratory Services Agreement for Long COVID Panel Biomarker Partnership with Amerimmune Diagnostics
Aug. 05, 2022
Todos Medical Initiates Validation Plan for PCR-based MonkeyPox Test at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics
Aug. 03, 2022
Todos Medical Announces Preprint of Acute COVID-19 Paxlovid Rebound Rescued by Tollovid
Aug. 01, 2022
Todos Medical Partners with Amerimmune Diagnostics on Long COVID Biomarker Panel
Jul. 28, 2022
Todos Medical Announces Preprint of Chronic Long COVID Case Study #8 of Paxlovid® Treatment Followed by Tollovid™ Dietary Supplementation
Jul. 22, 2022
Todos Medical Reports Case Study #7 in Acute and Long COVID
Jul. 12, 2022
Todos Medical Announces Positive Biomarker Data from Phase 2 Trial of Tollovir in Hospitalized COVID-19 Patients
Jun. 30, 2022
Todos Medical Releases Preliminary Data From IRB-Waived Tollovid® Market Research Study in Acute and Long COVID
Jun. 23, 2022
Todos Medical Retains Moneta Advisory Partners as Strategic Advisors for National Exchange Listing and 3CL Pharma Spinoff
Jun. 21, 2022
Todos Medical Completes Validation of 27 Pathogen UTI PCR Panel at Its CLIA/CAP Laboratory Provista Diagnostics
Jun. 13, 2022
Todos Medical Reports Day 45 Update for Case Study #6
Jun. 10, 2022
Todos Medical Reports Day 28 Update for Case Study #5 with Erectile Dysfunction
Jun. 07, 2022
Todos Medical Announces Enrollment Complete for Confirmatory Cohort of LymPro Alzheimer’s Blood Test Clinical Validation Trial vs. Amyloid PET
Jun. 03, 2022
Todos Medical Reports Day 26 Update For Case Study #4
Jun. 01, 2022
Todos Medical to Present Final Data from the Tollovir Phase 2 Clinical Trial in Hospitalized COVID-19 Patients at the Personalized Medicine World Conference
May 27, 2022
Todos Medical Reports Day 14 Update from Ongoing 30-Day Case Study of Paxlovid Rebound Patient
May 06, 2022
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength Including 5 Day Dosing, 30 Day Dosing and 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim
May 02, 2022
Todos Medical Initiates IRB-Waived Tollovid Market Research Study and Announces 50% Price Reduction Until May 30th, 2022
Apr. 27, 2022
Todos Medical Appoints Philippe Goix as Chief Commercial Officer for Provista Diagnostics
Apr. 21, 2022
Todos Medical Reports 2nd Long COVID Case Study and Launches Website for Physicians and Pediatricians to Indicate Interest in Participating in Tollovid Long COVID Clinical Study
Apr. 20, 2022
Todos Medical Targets Athlete Support with Informed Sport Certification for Tollovid by LGC Group
Apr. 19, 2022
Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate of Free Sale with Daily and Acute Dosing on the Label
Apr. 06, 2022
Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants
Apr. 04, 2022
Todos Medical Reports Case Study of Patient with Long COVID
Mar. 31, 2022
Billy Blanks® Endorses Todos Medical’s Line of Tollovid® Products
Mar. 28, 2022
Todos Medical Completes Acquisition of Key Assets and Intellectual Property from NLC Pharma
Mar. 16, 2022
Todos Medical Appoints Greg Meiselbach as Vice President of Government Affairs
Mar. 08, 2022
Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients
Jan. 27, 2022
Todos Medical Announces Data Lock in Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
Jan. 24, 2022
Pepperdine University Hosts the 22nd Annual Celebrity Flag Football Challenge®, Presented by Todos Medical’s Tollovid®
Jan. 19, 2022
Todos Medical Releases Videos of Recent CEO Interviews with Fox Business, NewsMax and Black News Channel on COVID Testing & Treatment Strategies
Jan. 18, 2022
Todos Medical to Announce Topline Results from Tollovir™ Phase 2 Clinical Trial from the Treatment of Hospitalized COVID-19 Patients on January 27th, 2022
Jan. 12, 2022
Todos Medical CEO to Appear on Fox Business to Talk COVID Testing & Tollovir on Tuesday, January 11, 2022 and is Presenting at Biotech Showcase 2022
Jan. 10, 2022
Todos Medical Records Record Weekly COVID PCR Testing Volumes at Provista
Dec. 27, 2021
Todos Medical CEO to Appear on Yahoo Finance Live! at 12:10PM EST with Akiko Fujita to Talk Pfizer’s Paxlovid Approval, Tollovir™ Phase 2 & COVID Testing
Dec. 23, 2021
Todos Medical Announces New cPass Neutralizing Antibody Testing Reference Lab Agreement for CLIA/CAP Lab Provista with Physician Group in 40 States
Dec. 22, 2021
Todos Medical Appoints Valentino Smith, MBA as Vice President of Marketing
Dec. 20, 2021
Todos Medical Announces “Test & Tollovid®” Holiday Package for Atlanta Area at Provista Diagnostics
Dec. 17, 2021
Todos Medical to Host Key Opinion Leader Webinar Entitled Tollovir™: a Potential Treatment for Covid-19
Dec. 16, 2021
Todos Medical Enters 90-Day Extension of Agreement with Convertible Note Holders on Moratorium on Conversions of Convertible Notes
Dec. 13, 2021
Todos Medical Interview and Presentation on Benzinga's All Access Conference Live December 14th at 10:20 AM EST
Dec. 10, 2021
Todos Medical Announces 2 New COVID-19 PCR Testing Reference Lab Agreements for CLIA/CAP Lab Provista Diagnostics
Dec. 07, 2021
CEOs Presenting at the Emerging Growth Conference on December 8; Register Now
Dec. 07, 2021
Todos Medical to Present at Upcoming Emerging Growth Conference
Dec. 06, 2021
Todos Medical Announces All 31 Patients Enrolled to Date in Tollovir® Phase 2 Clinical Trial in Hospitalized COVID-19 Patients Have Completed Study Participation
Dec. 02, 2021
Todos Medical Confirms SARS-CoV-2 PCR Test Kits Used at CLIA/CAP Lab Provista Diagnostics Detect Omicron Variant
Nov. 30, 2021
Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma
Nov. 29, 2021
Todos Medical Receives Purchase Order for 50,000 Bottles of Tollovid Daily from Its European Distribution Partner T-Cell Protect Hellas S.A for Initial Market Launch in Greece
Nov. 22, 2021
Todos Medical Announces Completion of Enrollment for COVID-19 Oral Antiviral 3CLPro (Mpro) Inhibitor Tollovir Phase 2 Clinical Trial Interim Analysis in Severe and Critical Hospitalized Patients
Nov. 19, 2021
Todos Medical Announces Tollovid® Products Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. Covering 30 Countries in Europe
Nov. 18, 2021
Todos Medical Announces Addition of Semi-Quantitative Titer Claims to the Emergency Use Authorization for the cPass Neutralizing Antibody Test
Nov. 17, 2021
Todos Medical’s Provista Laboratory to Boost Top Line Through New Atlanta-based Reference Lab Agreement for COVID PCR, cPass Neutralizing Antibody & Respiratory Pathogen Panel Tests
Nov. 16, 2021
Todos Medical Reports Third Quarter 2021 Business and Financial Results
Nov. 15, 2021
Todos Medical Sees Significant Ramp Up in COVID PCR Testing Volume at Its Provista CLIA/CAP Lab with New Automation in Place
Nov. 02, 2021
Todos Medical Announces 2nd Clinical Trial Site for Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
Nov. 01, 2021
Todos Medical Announces Publication in Nature Neuroscience That Describes the Main Protease (3CL Protease) Causes Microvascular Brain Pathology
Oct. 25, 2021
Todos Medical Announces Publication in Journal of Clinical Virology Highlighting Clinical Utility of cPass Semi-Quantitative Neutralizing Antibody Test in SARS-CoV-2 Risk Assessment Post-Vaccination or Recovery from Infection
Oct. 21, 2021
Todos Medical to Conduct Webinar Highlighting the cPass SARS-COV-2 Neutralizing Antibody Test for AMDA, The Society for Post-Acute and Long-Term Care Medicine, on October 22, 2021 at 12:00 PM EDT
Oct. 14, 2021
Todos Medical Announces Positive Data in Hospitalized and Outpatient Setting for TolloTest™, a Novel SARS-CoV-2 3CL Protease Biomarker Assay
Oct. 06, 2021
Todos Medical Provides Update on COVID-19 Oral Antiviral 3CL Protease (Main Protease) Inhibitor Tollovir Clinical Development Program in Light of Molnupiravir Clinical Trial Data from Merck
Oct. 04, 2021
Todos Medical Announces Positive Observational Trial Results for Oral Antiviral 3CL Protease (MPro) Inhibitor Tollovir®
Sep. 30, 2021
Todos Medical Receives Approval by Amazon to Sell Immune Supplements Tollovid® & Tollovid Daily™
Sep. 27, 2021
Todos Medical Reports Second Quarter 2021 Financial Results
Fri, Sep. 24, 2021
UPDATE: Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders
Sep. 24, 2021
Todos Medical Launches Tollovid Daily™ via Subscription at MyTollovid.com
Sep. 23, 2021
Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Oral Antiviral Drug Candidate Tollovir™
Sep. 20, 2021
Todos Medical Now Accepting Cryptocurrency for the Purchase of Tollovid® and Tollovid Daily™ Through Coinbase Commerce
Sep. 17, 2021
Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders
Sep. 15, 2021
Todos Medical’s CLIA/CAP Lab Provista Completes Validation of Combination COVID, Influenza A & B, RSV & hMPV Respiratory Panel Test
Sep. 01, 2021
Todos Medical’s CLIA/CAP Lab Provista Completes Validation of High-Capacity SARS-CoV-2 Variant Testing Service Capable of Identifying Known Variants
Aug. 26, 2021
Todos Medical’s CLIA/CAP Lab Provista Enters Into Reference Lab Agreement with Meadowlands Diagnostics to Provide cPass Neutralizing Antibody Blood Testing for Quantifying and Monitoring Key COVID-19 Immunity Biomarkers
Aug. 24, 20211
Todos Medical Completes Validation of cPass Neutralizing Antibody Blood Test at Provista Diagnostics to Quantify and Monitor Key Biomarkers of COVID-19 Immunity
Aug. 23, 2021
Todos Medical CEO to Appear on Fox Business Network Varney & Company Today at 11:40am to Discuss the Company’s Launch of cPass Neutralizing Antibody Testing for Monitoring COVID-19 Immunity
Aug. 23, 2021
Update: Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Dietary Supplement Tollovid™
Aug. 05, 2021
Todos Medical Receipt Notice of Allowance from USPTO for 3CL Protease Inhibitor Dietary Supplement Tollovid™
Aug. 05, 2021
Todos Medical Makes Final Payment to Close Provista Diagnostics Acquisition
Aug. 02, 2021
Todos Medical Retains CRO for COVID-19 Outpatient and Inpatient Phase 2/3 Clinical Trials for Oral Antiviral 3CL Protease Inhibitor Tollovir
Jul. 28, 2021
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid Daily™ Including 3CL Protease Inhibitor Claim
Jul. 22, 2021
Todos Medical to Launch EUA Authorized cPass SARS-CoV-2 Neutralizing Antibody Kit Through Agreement with Fosun Pharma
Jul. 19, 2021
Todos Medical Appoints Ilanit Halperin, CPA as Corporate Controller
Jul. 07, 2021
Todos Medical Receives FDA Certificate of Free Sale for New 5-Day Tollovid Dosing Regimen
May 04, 2021
Todos Medical Launches Phase 2 Clinical Trial of Its Antiviral 3CL Protease Inhibitor NLC-V-01 (Tollovir) in Hospitalized COVID-19 Patients
Apr. 19, 2021
Todos Medical Receives Notice of Allowance from European Patent Office for Patent Application Covering Diagnosis of Cancer Using Proprietary Artificial Intelligence TBIA Immune Profiling Platform
Apr. 08, 2021
Todos Medical Completes Automation Equipment Installation and Training for Meadowlands Diagnostics
Apr. 01, 2021
Todos Medical Enters Into Distribution Partnership with Osang Healthcare for the GeneFinder Plus™ COVID-19 Plus RealAMP Kit in the United States
Mar. 30, 2021
Todos Medical Completes Automation Equipment Installation and Training for a Laboratory Client in Brooklyn, NY
Mar. 29, 2021
Todos Medical Enters Into Automation and Reagent Supply Agreement with MAJL Diagnostics
Mar. 23, 2021
Todos Medical Announces $7.2M in Sales for February 2021, a 38% Month Over Month Increase From Sales of $5.2M in January 2021
Mar. 12, 2021
Todos Medical Applauds Senate and House Passage of the American Recovery Act
Mar. 11, 2021
Todos Medical Announces Strategic Investment by Yozma Group Korea
Jan. 25, 2021
Todos Medical Announces $4.8 Million in Sales for December 2020, a 50% Month Over Month Increase in Sales from November 2020
Jan. 11, 2021
Todos Medical Announces Agreement to Supply Natural Wellness Clinics with COVID-19 Testing Products to Support Initiatives in the Commonwealth of Kentucky
Dec. 23, 2020
Aditxt Signs Distribution Agreement with Todos Medical Ltd. For AditxtScore™ for COVID-19 Immune Monitoring Service
Dec. 14, 2020
Todos Medical Announces Commercial Launch of Proprietary 3CL Protease Inhibitor Dietary Supplement Tollovid™ at The Alchemist’s Kitchen
Dec. 07, 2020
Todos Medical Announces $3.2 Million in Sales for November 2020, a 269% Increase Sequential Month over Month Sales Growth from October 2020
Dec. 02, 2020
Todos Medical Provides Strategic Outlook
Dec. 01, 2020
Todos Medical Completes Installation of Lab Automation Equipment at Wisconsin Lab Client to Support COVID-19 PCR Testing
Nov. 24, 2020
Todos Medical Announces Positive In Vitro Data for Tollovid™ Confirming 3CL Protease Inhibition Mechanism of Action
Nov. 20, 2020
Todos Medical Announces Positive Initial Clinical Proof-of-Concept Data for a Rapid SARS-CoV-2 3CL Protease Detection Assay
Nov. 18, 2020
Todos Medical Announces Clinical Validation and National CLIA Certification for MOTO+PARA Mobile High Complexity Labs
Nov. 17, 2020
Todos Medical Announces $867,000 in Sales for October 2020
Nov. 12, 2020
Todos Medical Trademarks Tollovid for Dietary Supplement NLC-001 and Enters Into Private Label & Distribution Agreement With The Alchemists Kitchen
Oct. 29, 2020
Todos Medical Announces Instrument Validation Complete at MOTO+PARA Mobile Lab
Oct. 26, 2020
Todos Medical Announces Distribution Agreement with Adial Pharmaceuticals to Market the FDA, EUA Authorized, Assure/FaStep Point-of-Care Covid-19 Antibody Tests
Oct. 22, 2020
Todos Medical Receives Notices of Allowance From the European Patent Office Covering Use of TBIA Cancer Platform to Detect Benign Colon Cancer
Oct. 20, 2020
Todos Medical Reports $2.0 Million in Revenue for the Third Quarter of 2020
Oct. 13, 2020
Todos Medical Enters into Exclusive COVID-19 Testing Supply Agreement with MOTO+PARA’s National Mobile CLIA Lab Partner Integrated Health
Oct. 07, 2020
Todos Medical Enters into Exclusive Branding and Distribution Agreement with Melbourne Biotech for 96 and 384 Well RT-PCR Machines in the United States
Sep. 30, 2020
Todos Medical Enters Into COVID-19 PCR Testing Implementation and Equipment Financing Partnership with AID Genomics
Sep. 25, 2020
Todos Medical Expands Existing Contract for COVID-19 PCR Testing Equipment & Supplies with Wisconsin-based Laboratory to $47.5 Million
Sep. 22, 2020
Todos Medical CEO Releases Letter to Shareholders
Sep. 18, 2020
3CL Protease Inhibitor NLC-001 Added to COVID-19-focused Joint Venture Between Todos Medical and NLC Pharma
Sep. 17, 2020
Todos Medical Expands Partnership with Care G.B. Plus for Proprietary TBIA Cancer Tests to Include Europe, Israel and Africa
Sep. 16, 2020
Todos Medical Announces Commercial Launch of Todos Branded COVID-19 qPCR Test Kits in the United States
Sep. 11, 2020
Todos Medical Announces August Sales of $1,190,000, Up 100% Compared with July
Sep. 03, 2020
Todos Medical Enters Into Partnership With Pangea for COVID-19 Testing and Contact Tracing
Sep. 02, 2020
Todos Medical Announces $23,760,000 Contract for COVID-19 PCR Testing Equipment & Supplies With Wisconsin-based Laboratory
Aug. 31, 2020
Todos Medical to Present at The LD 500 Virtual Conference
Aug. 31, 2020
Todos Medical Announces $4,500,000 Contract for COVID-19 PCR Testing Equipment & Supplies with New York-based Laboratory
Aug. 27, 2020
Todos Medical Appoints Marsha Fontanive as VP of Sales and Chris Gross as VP of Sales Operations
Aug. 25, 2020
Todos Medical Announces $1.2 Million Contract for COVID-19 PCR Testing Equipment & Supplies with Texas-based Laboratory
Aug. 24, 2020
Todos Medical Announces $6,000,000 Contract for COVID-19 PCR Testing Equipment & Supplies with New York-based Laboratory
Aug. 21, 2020
Todos Medical Announces Positive Proof-of-Concept Data for Novel 10-Minute Point-of-Care Saliva-based Test Detecting Active SARS-CoV-2 Infection
Aug. 17, 2020
Todos Medical Acquires Distribution Rights to SARS-CoV-2 Rapid Point-of-Care Antigen Test and Rapid Point-of-Care PCR Test
Aug. 14, 2020
Todos Medical Announces July Sales of COVID-19 Tests
Aug. 07, 2020
Todos Medical Announces Common Stock Purchase Agreement with Lincoln Park Capital Fund, LLC
Aug. 06, 2020
Todos Medical Appoints Dr. Jorge Leon as Consulting Chief Medical and Scientific Officer of Infectious Disease and Oncology
Aug. 04, 2020
Pathnova Laboratories (PATHNOVA) Enters into Partnership to Commercialize Todos Medicals COVID-19 and Breast Cancer Tests in Singapore
Aug. 03, 2020
Todos Medical Completes Acquisition of Breakthrough Diagnostics, Gains Full Rights to the Alzheimer’s Blood Diagnostic LymPro™ Test from Amarantus
Jul. 28, 2020
Todos Medical Announces SARS-nCoV-19 Testing Kit Contract with NJ-Based Best Supply Clinical Laboratory
Jul. 27, 2020
Todos Medical Expands Management Team and Advisory Board
Jul. 20, 2020
Todos Medical Announces ANVISA Authorization in Brazil for 3D Med qPCR Kits and ANDis Extraction S
Jul. 16, 2020
Todos Medical Releases Letter to Shareholders
Feb 07, 2020 9:15am EST
Todos Medical Enters into Exclusive Option Agreement to Acquire Provista Diagnostics and Announces Management Changes
Jan 09, 2020 8:00am EST
Todos To Present At Upcoming 12th Annual LD Micro Main Event
Dec 06, 2019 7:29am EST
Todos and Amarantus JV Announces Full Enrollment for Clinical Trial of LymPro Alzheimer’s Blood Test Relationship with Amyloid PET
Nov 14, 2019 11:02am EST
Todos Medical to Present at Dawson James Small Cap Growth Conference
Oct 24, 2019 9:25am EDT
Todos Medical and Orot+ Announce First Patient Enrolled in Pre-Commercial Launch Preparations of TM-B1 and TM-B2 Breast Cancer Blood Screening Tests in Europe
Sep 24, 2019 9:14am EDT
Todos Medical Signs Binding Term Sheet with HWH World for Network Marketing of Blood Tests for the Early Detection of Breast Cancer
Sep 13, 2019 7:30am EDT
Todos Medical Enters into MOU to Expand Existing Early Detection Breast Cancer Blood Test Distribution Partnership with Orot+ into Japan
Sep 03, 2019 1:29pm EDT
Todos Medical Appoints Dr. Jorge Leon as Medical Advisor
Aug 06, 2019 7:00am EDT
Todos Medical Announces Positive Alzheimer's Biomarker Clinical Data from LymPro vs. Amyloid PET Interim Analysis
Jul 15, 2019 7:00am EDT
Todos Medical CEO Presented Corporate Update And Roadmap at The LD Micro Conference
Jun 17, 2019 8:30am EDT
Todos Medical Announces Positive Clinical Trial Data for Breast Cancer Blood Test TM-B1 in Dense Breasts
Jun 03, 2019 8:00am EDT
Todos Medical Exercises Option to Acquire Remaining 80.01% of Breakthrough Diagnostics from Amarantus After Review of Alzheimer's Blood Test Data
May 28, 2019 8:57am EDT
Todos Medical Receives Approval from Israeli Ministry of Health (AMAR) to Market and Sell its Breast Cancer Screens in Israel
May 23, 2019 8:00am EDT
Todos Medical Enters Exclusive Distribution Agreement with Care G.B. Plus, Ltd. for its Breast Cancer Screening Tests in Israel
May 21, 2019 8:00am EDT
Todos Medical Announces Voting Results from 2019 Annual Shareholder Meeting
May 03, 2019 8:52am EDT
Todos Medical Receives Notice of Allowance from the USPTO Covering the Early Diagnosis of Lung Cancer Using the Todos Biochemical Infrared Analysis (TBIA)
May 01, 2019 8:00am EDT
Todos Medical Enters Into Definitive Agreement With Orot+ for Exclusive Distribution Rights of its Breast Cancer Screening Tests in 2 European Countries
Apr 15, 2019 8:00am EDT
Todos and Amarantus Announce Completion of LymPro PET 1 Study by Leipzig University for Alzheimer’s Blood Diagnostic LymPro Test 2.0
Apr 08, 2019 7:30am EDT
Todos Medical to Present at Two Upcoming Investor Conferences
Mar 28, 2019 8:00am EDT
Todos Medical Appoints Dr. Colin Bier to Its Board of Directors
Mar 27, 2019 8:00am EDT
Todos Medical Raises $1,350,500 In Funding and Finalizes Joint Venture Agreement with Amarantus Bioscience
Feb 28, 2019 9:30am EST
Todos Medical Presents Encouraging Scientific Abstract at the San Antonio Breast Cancer Symposium (SABCS)
Dec 06, 2018 4:00pm EST
Todos Medical Enters into Joint Venture Agreement with Amarantus to develop Alzheimer’s Blood Diagnostic LymPro Test 2.0
Dec 03, 2018 8:30am EST
Todos Medical to Present Scientific Abstract at the Upcoming San Antonio Breast Cancer Symposium (SABCS)
Nov 29, 2018 8:30am EST
Todos Medical, Ltd. Announces Additional Patent Issuance Covering the Use of IR Spectrum of Blood Plasma For Indicating the Presence of Breast Cancer
Oct 17, 2018 8:30am EDT
Todos Medical, Ltd. Signs Non-Binding Memorandum of Understanding with Orot+ for Distribution Rights of its Breast Cancer Screening Tests in Romania and Austria
Sep 13, 2018 8:30am EDT
Todos Medical, Ltd. Appoints Herman Weiss, MD MBA as New Chief Executive Officer
Jul 31, 2018 4:03pm EDT
Todos Medical reports on results of clinical trials for its blood test for breast cancer screening (TM - B1) conducted at Kaplan Hospital in Rehovot, Israel
Mar 22, 2018 8:00am EDT
Todos Medical initiates clinical trial of its blood test for breast cancer in Kaplan Hospital, Rehovot, Israel for subjects undergoing breast cancer screening
Mar 05, 2018 8:00am EST
U.S. Patent and Trademark Office has granted to Todos Medical two additional patents
Feb 12, 2018 8:00am EST
Mr. David Ben Naim, CPA, MBA Joins Todos Medical as Chief Financial Officer
Feb 06, 2018 8:00am EST
Todos Medical Appoints Dr. Meir Silver as Vice President of Clinical Research and Regulatory Affairs
Aug 29, 2017 8:30am EDT
wowza - Gerald says it all right here folks....!
‘Life is Good’ my friend….
It’s all in ones free choice and will in how to look at it.
I’m a firm believer in the fact that in life, every cloud has a silver lining. You have a God given opportunity to see the silver lining in each and every one that life presents us.
In the infamous words of Wayne Dyer,
Printing $0.0004 - Yikes Joey Yikes...!
cozy up my pearly right cheek arse...!
don't 'PRETEND' like you know what that AMBS CTJ meeting was all about...
between the twice failed CEO wannabe Stanford undergrad "Financial Engineering" hack & double talking scammer and me
cause IMHO you know nothing - nada - nil - zilch - you are a fake and a phony - nothing more - nothing less...!
but you and your AMBS & TOMDF Back Office Promo Pumper Boyzzz keep obfuscating around the what the 'REAL DEAL' is...
or what the 'REAL ISSUE' issue is here - by trying to make me look like the bad guy - right "JOEY"
when in fact this is what has gone on, both in AMBS & TOMDF - which you were relentlessly pumping under multiple aliases:
and because you haven't been forthcoming & honest with the posters on both AMBS & TOMDF threads
here's what the SS now looks like as a result:
into the float yes folks that BILLION shares folks...!
its enough to strangle any investors out of their hard earned honest $$$
by dropping the floor out of the bottom and causing a catastrophic -99% loss to the share price
read it and weep - cause all those TOMDF average-down buys you constantly posted about are all under $0.0004 pps water
unless of course it was your whole intention to entice the unsuspecting novice investor into thinking you were buying
when in reality you weren't - were you...?
so which one is it Warp - no need to answer that - as its a rhetorical question
we all know your real MO and your sullied reputation around these parts - we are are on to you Pal...!
SMH - nuff said
MOO dolt
hey JoeyForks - or is it Warpspeed - so many aliases - so little time
anyway you're right on time pal...!
just like bus service - right to the front door
hey listen, who needs to respond when one's own credibility has been shown to be worthless...?
in their own words no less - just how smart is this self conceived post - Duh...!
as stated before - here's all you really need to know about your TOMDF atrocity
and TOMDF's Stanford University"Financial Engineer" hack and twice failed wannabe CEO:
along with 300-Bil. OS's already issued and in the diluted float
yes that "BILLION" folks - freakin YIKES...!
and just in case all that chokes one up
here's a chaser to wash the TOMDF TURD down with:
oh, and in case one is feeling left out
here's a Disney Donald Duck anonymous keyboard
so you can keep you bud Redspudder company and can play together:
SMH - nuff said - you simply can't make this shite up...!
TOMDF Back Office Promo Boyzzz at it again - hilarious.
surprisingly enough, Joeyforkeybolo has less followers than his faithless side kick Wordman
what a hoot folks:
MOO dookie in bam bam
good one Wordie....or is it Redspeed...?
so many posts starting to sound the same - so many aliases to keep up with - Ugh...!
distorted and fabricated realities remain alive and well I see...!
meanwhile back at the ole' TOMDF coral
the "ONLY" thing that matters and that actually replaces pesky MB sophomoric banter is this:
got to love those Astoria Queens financial mafia guys
and they're seedy underhanded dilutive financing
MOO dunce
what hooie...!
BAF MONI...
MONi will surprise
holding for it…!
BAF MONI
yeah like Les says - how about that Case #
along with that PACR link
doubt its my case - for reasons that will remain undisclosed
but you just go ahead and continue throwing insults at me
they only define who "you" are
he can’t - he doesn’t own any MONI shares
never did - strange but true
can’t make this stuff up…
BAF MONI
no stock analyst - never was - never will be
however, I know your AMBS TOMDF & VERB catastrophic share price losses hurt - bigley...!
especially the reputation thingy - and the trove of financially hurt faith filled followers you amassed...
but hey - not all's lost - look at it this way Red....
just like JFB - you can change your alias multiple times and start anew - eh "Red"
just sayin for my friend - Jordan Belfort - of course
SMH - nuff said
MOO tout
free or not free...
I'll choose to take-up whatever it is with whomever I choose to
yip thats my name...
and damn proud of it - there's no need for me to hide behind my keyboard, like yours shown below:
here's all that anybody really needs to know - as words are cheap and often misleading - eh Red...?
here's your atrocious eye popping, nose bleed, jaw dropping, empty pockets picture in full living color:
but hey, keep leading the TOMDF BackOffice Promo Boys pump room
you & JFB have done exceptionally well so far...!
SMH - nuff said
MOO tout
the contract for MONI's control block being executed by both parties and changing hands
followed by Scott Harmolin's announcement as new MONI BOD member & President
were 2 key milestone changes that can not be refuted
what's next - is where MONI's direction will take us
time for MONI to finally Whoop Some Arse...!
BAF MONI
just a few things anyone has to know
about one's own TOMDF or AMBS credibility
apparently being in the TOMDF Back Office Promo Boy pumping club
didn't help your other fake alias moniker Warpspeed with AMBS either
words are meaningless "Joey" - however pictures can not be refuted - just lookie here:
gheesh talk about real clown acts...
SMH - nuff said
MOO shill
wondering in Frank Benedetto will pick back up on MONI this week
mo mo MONI...!
what absolute hooie…!
can’t believe I wasted precious eye movement on the pile
MONI will surprise…
BAF MONI